Literature DB >> 35765396

Infective Endocarditis Complicated With Septic Embolic Stroke After Transcatheter Aortic Valve Implantation: A Case Report.

Suchapa Arayakarnkul1, Koravich Lorlowhakarn1, Sarinya Puwanant2, Suphot Srimahachota2, Aekarach Ariyachaipanich3.   

Abstract

Transcatheter aortic valve implantation (TAVI) is a relatively novel procedure developed for aortic stenosis (AS) management in patients with moderate to high surgical risk, especially the elderly with multiple comorbidities. Infective endocarditis following transcatheter aortic valve implantation (post-TAVI-IE) is an uncommon complication that contributes to very high morbidity and mortality. Further complications from post-TAVI-IE include ischemic stroke from septic emboli. Here, we report a case of an 82-year-old man with severe symptomatic AS who underwent TAVI, presenting with fever and alteration of consciousness, which was diagnosed as post-TAVI-IE per Duke criteria complicated by acute hemiparesis from septic emboli stroke. He was treated successfully conservatively using antibiotics. We have reviewed the options of treatment and outcomes for post-TAVI-IE.
Copyright © 2022, Arayakarnkul et al.

Entities:  

Keywords:  infective endocarditis; prosthetic valve endocarditis; stroke; tavi; tavr; transcatheter aortic valve implantation; transcatheter aortic valve replacement

Year:  2022        PMID: 35765396      PMCID: PMC9233737          DOI: 10.7759/cureus.25379

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Aortic stenosis (AS) is a slowly progressive condition with increasing prevalence with advancing age and is one of the most commonly encountered valvular diseases worldwide. Once it produces symptoms such as dyspnea, chest pain, or heart failure, it is already in advanced stages. Transcatheter aortic valve replacement (TAVI) has been developed as a novel intervention to target elderly patients who hold moderate to high risks [1] to undergo surgical aortic valve replacement (SAVR) in severe stages, as defined by reduced valve area and high flow gradient across the aortic valve, and symptomatic AS patients with high risk for surgical intervention whose life expectancy is greater than one year [2]. Due to its less invasive nature, this fragile group of patients had a better chance of post-intervention recovery. Typical post-TAVI complications include permanent pacemaker implantation due to postoperative high-grade atrioventricular block, paravalvular regurgitation, and infection including infective endocarditis [3]. Infective endocarditis following transcatheter aortic valve implantation (post-TAVI-IE) is a serious complication with very high morbidity and mortality rates; 80% of the patients meet the criteria for surgical intervention and are reported to have a 75% mortality rate in one year [2,4]. This itself is a paradox since patients initially selected for TAVI procedures in the first place are the group that was previously deemed unfit for surgery. Therefore, despite a high proportion of patients having met the indication for surgical intervention, most cases were managed conservatively. Data on the mortality rates between surgical and conservative treatment have suggested the survival rates to be comparable [4,5], but the data is still very limited. There is still a gap in knowledge regarding the most appropriate course of action in the management of TAVI-IE. Here, we report a case of an 82-year-old man with severe symptomatic AS who underwent TAVI, presenting with fever and alteration of consciousness, and was diagnosed as post-TAVI-IE per Duke criteria complicated by acute hemiparesis from a septic embolic stroke.

Case presentation

An 82-year-old patient with severe AS and ureteral stricture with nephrostomy who recently underwent TAVI presented with fever and alteration of consciousness. He had a history of fever for the past week, as confirmed by the body temperature of 38.3°C at presentation. Physical examination was notable for a diastolic murmur and valve clicks at the right parasternal border. No splinter hemorrhage, Janeway lesions, or Osler nodes were noted. Three months prior to this presentation, the patient was diagnosed and treated for non-ST elevation acute coronary syndrome and severe calcific AS with acute heart failure. Due to high operative mortality risk as assessed with the Society of Thoracic Surgeons (STS) score of 9.7% (cut-off value for high risk = 8%), percutaneous coronary intervention (PCI) and TAVI were performed instead of open surgery. During EvolutR #34 mm (Medtronic, Minneapolis, Minnesota) valve deployment, his electrocardiogram turned to a complete atrioventricular block, necessitating a permanent pacemaker insertion. Post-implantation ventriculography showed a well-seated aortic prosthesis with mild paravalvular leakage at 7 o’clock with no residual pressure gradient between the aorta and the left ventricle. The left ventricular ejection fraction was increased from 48% to 64%, and the patient was discharged. During this subsequent admission, the initial workup for the source of fever revealed marked leukocytosis (16,170/μL, neutrophil 87.8%) and numerous white blood cells on urinalysis. Therefore, he was initially treated for urinary tract infection. On the third day of admission, the patient developed a sudden-onset right hemiparesis. Brain computed tomography confirmed an acute infarction in the left parietal area. A transesophageal echocardiogram (TEE) showed a 6 mm x 10 mm mobile mass at the anterior mitral leaflet with mitral regurgitation due to leaflet perforation, as shown in Video 1.
Video 1

Transesophageal echocardiogram showing vegetation at anterior mitral leaflet with mitral regurgitation due to leaflet perforation

Infectious workup reported Enterococcus faecalis in both blood and urine cultures. Having met two major Duke criteria for IE, the patient was diagnosed with infective endocarditis after transcatheter aortic valve implantation (TAVI-IE) with septic embolic stroke. Considering septic emboli stroke complicating IE, our patient is indicated for surgery; nevertheless, taking into account the multiple comorbidities and high surgical risks, conservative treatment was decided upon. Antibiotics were switched to ampicillin and ceftriaxone. Following two weeks of intravenous antibiotics, he developed a new onset of fever. Blood culture was positive for Pseudomonas aeruginosa, which was thought to have been sourced from his nephrostomy. Intravenous ciprofloxacin was added to the regimen. A follow-up transthoracic echocardiogram (TTE) was done following four weeks of antibiotics, which showed a decreased size of the mitral valve vegetation at 4 mm x 8 mm. There is a newly seen 7-mm ventricular septal defect with left-to-right intracardiac shunt as shown as a high-velocity flow in the right ventricular chamber during systolic phase shown in Video 2.
Video 2

Transthoracic echocardiogram showing ventricular septal defect with left-to-right intracardiac shunt after infective endocarditis resolution

All three antibiotics continued for the duration of six weeks. In the following year, the patient returned to the hospital due to episodes of pseudomonal septicemia, all of which were managed conservatively with six weeks of intravenous antibiotics. The source of infection was suspected to be his nephrostomy, which the multidisciplinary team meeting had recommended removal. To date, two years after TAVI, the patient is still alive and did not develop any additional complications.

Discussion

This case demonstrates post-TAVI-IE in a severe AS patient who underwent TAVI and later developed septic embolic stroke as a further complication. Post-TAVI-IE [6] itself is described to affect 0.3%-1.2% of all patients who underwent the procedure [7]. Male gender (proposed to be owing to poor dental and urologic hygiene), chronic kidney disease (due to frequent intravascular manipulation from hemodialysis), and a new pacemaker implantation (as an entry route for pathogen and endocardial lesion during insertion procedure) are found to be associated with post-TAVI-IE. Diagnosis of post-TAVI-IE utilizes the modified Duke criteria [8]. The most common presentations are fever and heart failure [5], usually presenting within one-year post-procedure. The median time is at 5.4 months. Most frequently isolated causative organisms are gram-positive bacteria such as streptococcus (25.3%), staphylococci (25.3%), and enterococci (24.1%), with Enterococcus spp. as a leading cause in patients who had undergone the transfemoral catheter route [9]. The all-cause mortality of post-TAVI-IE has been reported to be as considerable at 75% one year after diagnosis [2]. Post-TAVI-IE may lead to various complications such as structural destruction (valvular regurgitation or ventricular septal defect), uncontrolled infection, or stroke. Risk factors for septic embolic stroke after TAVI include previous stroke (either at baseline or periprocedural TAVI stroke), residual aortic regurgitation more than or equal to moderate after TAVI, balloon-expandable valves, infective endocarditis within 30 days after TAVI, and vegetation size of more than 8 mm, especially those involving mitral valve. Incidence of stroke was reported to be at 6%-60% among those who underwent the procedure, with a higher probability in those with more risk factors. Mortality rates for this patient group were reported at 66% at one year [6]. Management of post-TAVI-IE and the following septic embolic stroke is a challenging medical dilemma. Persistent infection, uncontrolled embolism, or refractory heart failure may indicate an open-heart surgery [5,9], which was initially avoided in this group of patients who are deemed at high risk to undergo an operation. Therefore, despite having met indications for open-heart surgery, most patients were managed conservatively with antibiotics [10]. Previous literature on mortality rates comparing conservative and surgical management is still inconclusive. Some studies suggested the mortality rates are of no significant difference [4,5], while a meta-analysis reported a logistic regression model showing surgical treatment with self-expandable devices to relate to lower mortality [9]. Proposed management regarding post-TAVI-IE is shown in Table 1 with advantages and disadvantages of each modality, which include surgical intervention, conservative management, and very rarely, a TAVI-in-TAVI regarding post-TAVI-IE management [11].
Table 1

A literature review of infective endocarditis following transcatheter aortic valve implantation (post-TAVI-IE) management

MethodsAdvantagesDisadvantages
Open cardiac surgery [10,12]Eliminate the source of infection and correct structural abnormalities (i.e., dehiscence, paravalvular abscess, or fistula)High perioperative risk, extensive length of stay, and expense
Conservative treatment (antibiotics) [12]Noninvasive, comparable outcomes with surgical interventionProbability of infection relapse and incapable of structural damage management
Valve-in-valve procedure [7]Less invasive than open surgery, correction of aortic regurgitationVery limited data, reported to be performed only after infection resolution

Conclusions

Post-TAVI-IE is a serious complication following TAVI. This not uncommon complication leads to extensive morbidity and mortality. To date, no consensus management has been concerted. Since this patient population is very vulnerable to decompensation, the best effort should go toward its prevention. Nevertheless, in the event that post-TAVI-IE ensues, the most appropriate course of action varies, and individualized strategy should be discussed among the involved cardiovascular personnel and multidisciplinary team as deemed most fit to each patient’s distinctive setting.
  12 in total

1.  Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement.

Authors:  David Del Val; Mohamed Abdel-Wahab; Norman Mangner; Eric Durand; Nikolaj Ihlemann; Marina Urena; Costanza Pellegrini; Francesco Giannini; Tomasz Gasior; Wojtek Wojakowski; Martin Landt; Vincent Auffret; Jan Malte Sinning; Asim N Cheema; Luis Nombela-Franco; Chekrallah Chamandi; Francisco Campelo-Parada; Erika Munoz-Garcia; Howard C Herrmann; Luca Testa; Kim Won-Keun; Juan Carlos Castillo; Alberto Alperi; Didier Tchetche; Antonio L Bartorelli; Samir Kapadia; Stefan Stortecky; Ignacio Amat-Santos; Harindra C Wijeysundera; John Lisko; Enrique Gutiérrez-Ibanes; Vicenç Serra; Luisa Salido; Abdullah Alkhodair; Ugolino Livi; Tarun Chakravarty; Stamatios Lerakis; Victoria Vilalta; Ander Regueiro; Rafael Romaguera; Utz Kappert; Marco Barbanti; Jean-Bernard Masson; Frédéric Maes; Claudia Fiorina; Antonio Miceli; Susheel Kodali; Henrique B Ribeiro; Jose Armando Mangione; Fabio Sandoli de Brito; Guglielmo Mario Actis Dato; Francesco Rosato; Maria-Cristina Ferreira; Valter Correia de Lima; Alexandre Siciliano Colafranceschi; Alexandre Abizaid; Marcos Antonio Marino; Vinicius Esteves; Julio Andrea; Roger R Godinho; Fernando Alfonso; Helene Eltchaninoff; Lars Søndergaard; Dominique Himbert; Oliver Husser; Azeem Latib; Hervé Le Breton; Clement Servoz; Isaac Pascual; Saif Siddiqui; Paolo Olivares; Rosana Hernandez-Antolin; John G Webb; Sandro Sponga; Raj Makkar; Annapoorna S Kini; Marouane Boukhris; Philippe Gervais; Axel Linke; Lisa Crusius; David Holzhey; Josep Rodés-Cabau
Journal:  J Am Coll Cardiol       Date:  2021-05-11       Impact factor: 24.094

Review 2.  Transcatheter Aortic Valve Replacement: A Review.

Authors:  John H Braxton; Kelly S Rasmussen; Milind S Shah
Journal:  Surg Clin North Am       Date:  2017-08       Impact factor: 2.741

3.  Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death.

Authors:  Ander Regueiro; Axel Linke; Azeem Latib; Nikolaj Ihlemann; Marina Urena; Thomas Walther; Oliver Husser; Howard C Herrmann; Luis Nombela-Franco; Asim N Cheema; Hervé Le Breton; Stefan Stortecky; Samir Kapadia; Antonio L Bartorelli; Jan Malte Sinning; Ignacio Amat-Santos; Antonio Munoz-Garcia; Stamatios Lerakis; Enrique Gutiérrez-Ibanes; Mohamed Abdel-Wahab; Didier Tchetche; Luca Testa; Helene Eltchaninoff; Ugolino Livi; Juan Carlos Castillo; Hasan Jilaihawi; John G Webb; Marco Barbanti; Susheel Kodali; Fabio S de Brito; Henrique B Ribeiro; Antonio Miceli; Claudia Fiorina; Guglielmo Mario Actis Dato; Francesco Rosato; Vicenç Serra; Jean-Bernard Masson; Harindra C Wijeysundera; Jose A Mangione; Maria-Cristina Ferreira; Valter C Lima; Luiz A Carvalho; Alexandre Abizaid; Marcos A Marino; Vinicius Esteves; Julio C M Andrea; Francesco Giannini; David Messika-Zeitoun; Dominique Himbert; Won-Keun Kim; Costanza Pellegrini; Vincent Auffret; Fabian Nietlispach; Thomas Pilgrim; Eric Durand; John Lisko; Raj R Makkar; Pedro A Lemos; Martin B Leon; Rishi Puri; Alberto San Roman; Alec Vahanian; Lars Søndergaard; Norman Mangner; Josep Rodés-Cabau
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

4.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 5.  Clinical Practice Update on Infectious Endocarditis.

Authors:  Sami El-Dalati; Daniel Cronin; Michael Shea; Richard Weinberg; James Riddell; Laraine Washer; Emily Shuman; James Burke; Sadhana Murali; Christopher Fagan; Twisha Patel; Kirra Ressler; George Michael Deeb
Journal:  Am J Med       Date:  2019-09-12       Impact factor: 4.965

6.  Surgical versus medical management of infective endocarditis after TAVR.

Authors:  Agam Bansal; Wael A Jaber; Grant W Reed; Rishi Puri; Amar Krishnaswamy; James Yun; Shinya Unai; Samir R Kapadia
Journal:  Catheter Cardiovasc Interv       Date:  2022-01-23       Impact factor: 2.692

Review 7.  Transcatheter Aortic Valve Replacement in Intermediate- and Low-Risk Patients.

Authors:  Toby Rogers; Vinod H Thourani; Ron Waksman
Journal:  J Am Heart Assoc       Date:  2018-05-12       Impact factor: 5.501

8.  Cardiac Surgery Compared With Antibiotics Only in Patients Developing Infective Endocarditis After Transcatheter Aortic Valve Replacement.

Authors:  Norman Mangner; Sergey Leontyev; Felix J Woitek; Philipp Kiefer; Stephan Haussig; Christian Binner; Meinhard Mende; Florian Schlotter; Georg Stachel; Robert Höllriegel; Jennifer Hommel; Katrin Binner-Oussenek; Martin Misfeld; Holger Thiele; Michael A Borger; David Holzhey; Axel Linke
Journal:  J Am Heart Assoc       Date:  2018-09-04       Impact factor: 5.501

Review 9.  Surgical treatment of transcatheter aortic valve infective endocarditis.

Authors:  P G Malvindi; S Luthra; S Sarvananthan; A Zingale; C Olevano; S Ohri
Journal:  Neth Heart J       Date:  2020-10-06       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.